Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
bazedoxifene BZA-20 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| bazedoxifene BZA-20 | DRUG | - |
Inclusion Criteria: 1. Generally healthy Asian women 45 years of age or older who are at least 1 year postmenopausal 2. Subjects must qualify for one of the following categories (a or b): 1. Greater than 1 year but less than 5 years postmenopausal with at least one of the ospeoporosis risk fact...
Bazedoxifene BZA-20 is an investigational small molecule being studied for use in postmenopausal women, specifically for the treatment of postmenopause and osteoporosis. It is in Phase 3 clinical development and is not yet approved by regulatory authorities.
Bazedoxifene BZA-20 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
Bazedoxifene BZA-20 is currently in Phase 3 clinical development. It is an investigational drug, meaning it has not been approved for commercial use. One Phase 3 trial has been completed, and the drug is being evaluated for postmenopausal osteoporosis.
Bazedoxifene BZA-20 has been studied in one completed Phase 3 clinical trial, identified as NCT00384072. This trial evaluated the safety and efficacy of bazedoxifene in postmenopausal Asian women with osteoporosis, enrolling 500 participants across China, South Korea, and Taiwan.
Yes, bazedoxifene BZA-20 is a formulation of bazedoxifene, a selective estrogen receptor modulator. The designation BZA-20 refers to a specific investigational version being developed by Pfizer. It is being studied for postmenopausal osteoporosis and is not yet approved.